Detailed Information on Publication Record
2019
Is Computer-Assisted Aminoglycoside Dosing Managed by a Pharmacist a Safety Tool of Pharmacotherapy?
DVORACKOVA, E., P. PAVEK, B. KOVACOVA, Jitka RYCHLÍČKOVÁ, O. SUCHOPAR et. al.Basic information
Original name
Is Computer-Assisted Aminoglycoside Dosing Managed by a Pharmacist a Safety Tool of Pharmacotherapy?
Authors
DVORACKOVA, E. (203 Czech Republic, guarantor), P. PAVEK (203 Czech Republic), B. KOVACOVA (203 Czech Republic), Jitka RYCHLÍČKOVÁ (203 Czech Republic, belonging to the institution), O. SUCHOPAR (203 Czech Republic), M. HOJNY (203 Czech Republic), J. D. TEBBENS (203 Czech Republic) and J. VLCEK (203 Czech Republic)
Edition
Physiological research, Praha, Fyziologický ústav AV ČR, 2019, 0862-8408
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30105 Physiology
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 1.655
RIV identification code
RIV/00216224:14110/19:00112619
Organization unit
Faculty of Medicine
UT WoS
000499085100010
Keywords in English
Therapeutic drug monitoring; Aminoglycosides; Pharmacist; Nephrotoxicity; Pharmacokinetics
Tags
International impact, Reviewed
Změněno: 11/5/2020 10:44, Mgr. Tereza Miškechová
Abstract
V originále
This pilot prospective study verified the hypothesis that use of computer-assisted therapeutic drug monitoring of aminoglycosides by pharmacists leads to better safety therapeutic outcomes and cost avoidance than only concentration measurement and dose adjustments based on a physician's experience. Two groups of patients were enrolled according to the technique of monitoring. Patients (Group 1, n=52) underwent monitoring by a pharmacist using pharmacokinetic software. In a control group (Group 2, n=11), plasma levels were measured but not interpreted by the pharmacist, only by physicians. No statistically significant differences were found between the groups in factors influenced by therapy. However, the results are not statistically significant but a comparison of the groups showed a clear trend towards safety and cost avoidance, thus supporting therapeutic drug monitoring. Safety limits were achieved in 76 % and 63 % of cases in Groups 1 and 2, respectively. More patients achieved both concentrations (peak and trough) with falling eGFR in Group 1. In present pilot study, the pharmacist improved the care of patients on aminoglycoside therapy. A larger study is needed to demonstrate statistically significantly improved safety and cost avoidance of aminoglycoside therapy monitoring by the pharmacist using pharmacokinetic software.